Cigna Group Q2 FY26 earnings call CI

CEO Brian Evanko highlighted key themes emerging from discussions with partners: an elevated focus on affordability due to new expensive therapies and rising complex care demand; growing expectations for personalized experiences; and the need for actionable insights and clinical programs. These themes, coupled with economic pressures and AI advances, present opportunities for innovation. The company's strategy is aligned with these needs, driving strong Q2 performance ahead of expectations for both Evernorth and Cigna Healthcare.

Evernorth's earnings were slightly ahead of expectations, with revenues up 6% year-over-year. Specialty & Care Services pretax adjusted earnings grew 22% to $1.1 billion, fueled by secular tailwinds and differentiated strengths in Accredo and expanded Specialty Pharmacy Services. This growth was also driven by faster-than-expected adoption of specialty generics and biosimilars, which improve affordability. The company is uniquely positioned with access to over 330 limited distribution medicines and personalized clinical care teams.

Evernorth's Pharmacy Benefit Services reported pretax adjusted earnings of $609 million, down from the prior year, as expected. This reflects renewals of large client contracts and investments in the new rebate-free 'Signature' model. The Signature model is generating significant interest from health plans and employers, with a broader market launch planned for 2028, following its introduction to Cigna Healthcare's fully insured plans next year. The 2027 selling season has been strong, with new business exceeding the prior two seasons combined.

Cigna Healthcare delivered results ahead of expectations, with pretax adjusted earnings growing 17%. This was driven by a strong focus on the employer-sponsored market, disciplined pricing (including stop loss margin recapture), and strategic portfolio shaping. The company is innovating with data and clinical programs, such as provider matching for behavioral health and Headspace offerings, to improve access, affordability, and outcomes. Medical membership grew year-to-date, reflecting strong client relationships.

The Cigna Group is applying data, technology, and AI to improve customer outcomes, simplify experiences, and lower costs. Examples include 'Pharmacy Forward,' an AI-powered program expected to cut time to therapy in half and reduce clinician documentation time by up to 50%. AI-enabled care coordination capabilities are expanding to identify customers with complex health needs earlier, expected to reduce medical costs by approximately $2,000 per year and avoidable inpatient stays by 42% for engaged customers. This approach focuses on augmenting clinicians, not replacing them.

The company observed moderating GLP-1 growth in Q2, with slightly declined coverage and slowed utilization, a trend expected to continue. This moderation had a modest downward pressure on Pharmacy Benefit Services but was more than offset by Specialty business strength. Cigna also made the decision to discontinue financial support for GLP-1 drugs for weight management within its own employee health plan, citing affordability concerns and broader availability of options. This decision mirrors challenges faced by many clients, and the company offers various financing solutions for employers.

Management expressed concerns about abuses of the Independent Dispute Resolution (IDR) mechanism, noting unsustainable volume levels concentrated among a few providers. The majority of settlements favor providers, exacerbating affordability challenges for employers. In 2025, $15 billion in healthcare spending was processed through IDR, much of which is viewed as wasteful. While the impact has been manageable for Cigna Healthcare's planning and pricing, the issue remains a significant industry concern.